Mirum Pharmaceuticals, Inc. (MIRM)
NASDAQ: MIRM · Real-Time Price · USD
99.88
-1.03 (-1.02%)
Feb 11, 2026, 4:00 PM EST - Market closed
Mirum Pharmaceuticals Employees
Mirum Pharmaceuticals had 355 employees as of September 30, 2025. The number of employees increased by 44 or 14.15% compared to the same quarter last year.
Employees
355
Change
44
Growth
14.15%
Revenue / Employee
$1,328,997
Profits / Employee
-$116,685
Market Cap
5.98B
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Sep 30, 2025 | 355 | 44 | 14.15% |
| Jun 30, 2025 | 349 | 55 | 18.71% |
| Mar 31, 2025 | 334 | 56 | 20.14% |
| Dec 31, 2024 | 322 | 58 | 21.97% |
| Sep 30, 2024 | 311 | 62 | 24.90% |
| Jun 30, 2024 | 294 | 81 | 38.03% |
| Mar 31, 2024 | 278 | 78 | 39.00% |
| Dec 31, 2023 | 264 | 68 | 34.69% |
| Sep 30, 2023 | 249 | 55 | 28.35% |
| Jun 30, 2023 | 213 | 42 | 24.56% |
| Mar 31, 2023 | 200 | 56 | 38.89% |
| Dec 31, 2022 | 196 | 59 | 43.07% |
| Sep 30, 2022 | 194 | 57 | 41.61% |
| Jun 30, 2022 | 171 | 51 | 42.50% |
| Mar 31, 2022 | 144 | 59 | 69.41% |
| Dec 31, 2021 | 137 | 69 | 101.47% |
| Sep 30, 2021 | 137 | 70 | 104.48% |
| Jun 30, 2021 | 120 | 66 | 122.22% |
| Mar 31, 2021 | 85 | 44 | 107.32% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Caris Life Sciences | 1,769 |
| PTC Therapeutics | 939 |
| ImmunityBio | 673 |
| Crinetics Pharmaceuticals | 437 |
| Immunovant | 362 |
| Rhythm Pharmaceuticals | 283 |
| Kymera Therapeutics | 225 |
| Structure Therapeutics | 218 |
MIRM News
- 1 day ago - Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
- 6 days ago - Mirum Pharmaceuticals Announces Health Canada Authorization of LIVMARLI® Tablet Formulation for the Treatment of Cholestatic Pruritus in Patients with Alagille Syndrome - Business Wire
- 6 days ago - Mirum Pharmaceuticals Announces Health Canada Authorization of LIVMARLI® for the Treatment of Cholestatic Pruritus in Patients with Progressive Familial Intrahepatic Cholestasis (PFIC) - Business Wire
- 9 days ago - Top 3 Health Care Stocks That May Implode In Q1 - Benzinga
- 16 days ago - Mirum Pharmaceuticals Completes Acquisition of Bluejay Therapeutics, Expanding Global Leadership in Rare Disease - Business Wire
- 4 weeks ago - Mirum Pharmaceuticals, Inc. (MIRM) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript - Seeking Alpha
- 4 weeks ago - Mirum Pharmaceuticals Announces Preliminary Unaudited 2025 Results, Demonstrating Strong Commercial Growth and Pipeline Momentum - Business Wire
- 4 weeks ago - Enthorin Therapeutics Announces Initiation of Phase II Clinical Trial of MRM-3379 (Formerly ENT-3379) for Fragile X Syndrome by Licensing Partner Mirum Pharmaceuticals - Business Wire